Bryan Johnson, the 48-year-old American tech entrepreneur known for his extreme longevity protocol, announced in late June that he has autoimmune gastritis (AIG), a chronic disease with no known cure. The condition, in which the body’s immune system mistakenly destroys the stomach’s acid-producing parietal cells, had gone undetected for years despite persistently low ferritin levels. Johnson’s disclosure marks a significant setback for a figure who has built a global following around the idea that biological ageing can be halted and even reversed through rigorous self-experimentation.

AIG differs from common gastritis caused by H. pylori or lifestyle factors. It is a slow, often silent process that impairs absorption of vitamin B12 and iron, leading to anaemia, fatigue, and, over decades, an elevated risk of gastric cancer. Brazilian gastroenterologists consulted by local media note that the disease frequently coexists with other autoimmune disorders, such as the thyroid condition Johnson has managed since his early twenties. US-based specialists, however, caution against attributing the onset to past dietary habits or stress, as Johnson has done; the prevailing hypothesis points to a prior viral infection that triggers a cross-reactive immune response.

Johnson, who sold his payments company to PayPal for $800 million, frames the diagnosis as a new frontier. He will apply his Blueprint protocol’s data-intensive methods—$2 million annually on diagnostics and experimental therapies—to “try and solve” the condition. His team plans repeated biopsies, biomarker monitoring, and eventually bespoke interventions such as engineered proteins. Separately, his partner Kate Tolo will become the first woman on the full Blueprint regimen, with over $2 million per year to map female longevity markers.

The announcement has drawn attention to the limits of current medical knowledge on autoimmune gastritis. While standard care relies on B12 injections and iron infusions to manage symptoms, Johnson’s pursuit of a cure places him at the experimental edge of longevity science. Medical observers in Europe and the Americas note that his case highlights a broader tension: the growing commercialisation of anti-ageing protocols often outpaces clinical evidence. Johnson has stated he will share all findings publicly. The next concrete milestone will be the release of initial biopsy and biomarker data from his monitoring programme, expected in the coming months.